Skip to main content
STOK logo
STOK
(NASDAQ)
Stoke Therapeutics, Inc.
$32.74-- (--)
Loading... - Market loading

Stoke Therapeutics (STOK) Key Statistics & Financial Metrics

Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Market Valuation & Earnings Multiples

Market capitalization, P/E ratios, and enterprise value

Market Cap1.92B
Enterprise Value1.79B
Trailing P/E46.22

Price-Based Ratios

Valuation ratios based on stock price

Price/Sales (ttm)9.12
Forward Price/Sales3.04
Price/Book (mrq)6.09
Price/Tangible Book (mrq)6.09
Price/FCF (ttm)35.81
Price/OCF (ttm)35.48

Enterprise Value Ratios

EV-based valuation multiples

EV/Revenue8.73
EV/Earnings44.24
EV/EBITDA61.69
EV/EBIT65.98
EV/FCF34.27

Stock Price

Current price, 52-week range, and moving averages

Current Price$32.74
1-Day Change-1.75%
52-Week High$40.22
52-Week Low$5.35
52-Week Change413.48%
YTD Change3.53%
1-Year Change384.70%
50-Day MA$33.09
200-Day MA$25.85
Avg Volume (30 day)564.30K

Share Statistics

Outstanding shares, float, and per-share metrics

Shares Outstanding58.61M
Book Value per Share$5.26
Net Cash per Share$1.37
FCF per Share$0.89

Analyst Price Targets & Consensus

Wall Street analyst ratings and 12-month price targets (90 days)

Price Target$42.00
Target Upside/Downside28.28%
Analyst ConsensusStrong Buy
Analyst Count6

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Profit Margins

Profitability margins across income statement

Gross Margin99.52%
EBITDA Margin (ttm)14.15%
EBIT Margin (ttm)13.23%
Operating Margin (ttm)13.23%
Pretax Margin (ttm)19.73%
Profit Margin (ttm)19.73%
FCF Margin (ttm)25.47%

Return on Investment Metrics

ROE, ROA, ROIC, and capital efficiency ratios

Return on Equity (ttm)13.17%
Return on Assets (ttm)11.26%
Return on Invested Capital (ttm)11.95%
Return on Capital Employed (ttm)8.54%

Income Statement (TTM)

Trailing twelve months revenue and earnings

Revenue205.63M
Gross Profit204.64M
Operating Income27.20M
Pretax Income40.57M
Net Income40.57M
EBITDA29.09M
EBIT27.20M
Diluted EPS$0.69

Cash Flow (TTM)

Operating cash flow and free cash flow metrics

Operating Cash Flow52.85M
Capital Expenditures480.00K
Free Cash Flow52.37M

Growth Rates (YoY)

Year-over-year growth metrics

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Assets & Cash

Total assets and cash positions

Total Assets (mrq)360.26M
Cash & Securities (mrq)83.39M
Net Cash (mrq)80.49M
Net Cash per Share$1.37

Debt & Liabilities

Liabilities, debt, equity, and working capital

Total Debt (mrq)2.91M
Working Capital (mrq)230.71M
Total Equity (mrq)308.11M
Book Value per Share$5.26

Liquidity & Leverage

Liquidity, leverage, and debt coverage ratios

Current Ratio (mrq)6.53
Quick Ratio (mrq)6.53
Debt/Equity (mrq)0.01
Debt/EBITDA (ttm)0.10
Debt/FCF (ttm)0.06

Dividend History & Payout Analysis

Dividend yield, payout ratios, and growth metrics

Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%

Yield Metrics

Earnings, FCF, buyback, and shareholder yields

Earnings Yield2.16%
FCF Yield2.79%
Buyback Yield0.00%
Total Shareholder Yield0.00%

Financial Health Scores

Risk assessment and quality metrics

Altman Z-Score21.45
Piotroski F-Score4/9

Fair Value & Intrinsic Value

Lynch fair value, Graham number, and valuation models

Graham Number$9.05
Graham Upside/Downside-71.72%

Frequently Asked Questions About Stoke Therapeutics Statistics

What are the key financial metrics for STOK?

Stoke Therapeutics, Inc. (STOK) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is STOK's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Stoke Therapeutics is overvalued or undervalued.

How do I read STOK's profitability ratios?

Stoke Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do STOK's debt ratios indicate?

The financial health section shows Stoke Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is STOK's dividend analysis?

The dividend section covers Stoke Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.